Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4527226 open-label extension in early Alzheimer's disease
NL-OMON59185Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivisnebart in Alzheimer's disease (AD), sponsored by GSK. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence and severity of ARIA. Started Dec 2025; status: completed.
02
Drugs
nivisnebart
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON59185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59185.